Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for chronic postsurgical pain after lung cancer surgery
2026-525669-33-00Phase 2Authorised
- Sponsor
- Aalborg University Hospital
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in Persistent postsurgical pain (PPSP), sponsored by Aalborg University Hospital. Primary endpoints: Minimum participant inclusion, Eligibility and enrolment rate and 2 more. Planned start Aug 2026; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on 2026-525669-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525669-33-00.